Nintedanib: From discovery to the clinic

Journal of Medicinal Chemistry

Volumn 58, Issue 3, 2015, Pages 1053-1063

  Roth, Gerald J ^a   Binder, Rudolf ^a   Colbatzky, Florian ^a   Dallinger, Claudia ^a   Schlenker Herceg, Rozsa ^b   Hilberg, Frank ^c   Wollin, Stefan Lutz ^a   Kaiser, Rolf ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^c BOEHRINGER INGELHEIM RCV GMBH AND CO KG   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

NINTEDANIB; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR;

AREA UNDER THE CURVE; ARTICLE; CLINICAL RESEARCH; COLORECTAL CANCER; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FIBROSING ALVEOLITIS; HIGH THROUGHPUT SCREENING; HOSPITAL; HUMAN; HYPERTRANSAMINASEMIA; LIVER CELL CARCINOMA; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; ONCOLOGY; OVARY CANCER; PLASMA CONCENTRATION-TIME CURVE; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; THYROID CARCINOMA; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY EXCRETION; VOLUME OF DISTRIBUTION AT STEADY-STATE; ANIMAL; CHEMISTRY; DRUG DEVELOPMENT; FEMALE; IDIOPATHIC PULMONARY FIBROSIS; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; SYNTHESIS;

ANIMALS; DRUG DISCOVERY; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INDOLES; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PROTEIN KINASE INHIBITORS;

EID: 84922777723     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm501562a     Document Type: Article

References (55)

1. Roth, G. J.; Heckel, A.; Colbatzky, F.; Handschuh, S.; Kley, J.; Lehmann-Lintz, T.; Lotz, R.; Tontsch-Grunt, U.; Walter, R.; Hilberg, F. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120) J. Med. Chem. 2009, 52, 4466-4480
2. Roth, G. J.; Sieger, P.; Linz, G.; Rall, W.; Hilberg, F.; Bock, T. 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone monoethanesulphonate and the use thereof as a pharmaceutical composition. WO2004/013099. 2004.
3. Merten, J.; Linz, G.; Schnaubelt, J.; Schmid, R.; Rall, W.; Renner, S.; Reichel, C.; Schiffers, R. Process for the manufacture of an indolinone derivative. WO2009/071523. 2009.
4. Hilberg, F.; Roth, G. J.; Krssak, M.; Kautschitsch, S.; Sommergruber, W.; Tontsch-Grunt, U.; Garin-Chesa, P.; Bader, G.; Zoephel, A.; Quant, J.; Heckel, A.; Rettig, W. J. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy Cancer Res. 2008, 68, 4774-4782
5. Hilberg, F.; Brandstetter, I. Efficacy of BIBF 1120, a potent triple angiokinase inhibitor, in models of human non-small cell lung cancer is augmented by chemotherapy Eur. J. Cancer 2007, 2, S380
6. Wollin, L.; Maillet, I.; Quesniaux, V.; Holweg, A.; Ryffel, B. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis J. Pharmacol. Exp. Ther. 2014, 349, 209-220
7. Hostettler, K. E.; Papakonstantinou, E.; Klagas, J.; Karakiulakis, G.; Zhong, J.; Tamm, M.; Lardinois, D.; Roth, M. Anti-fibrotic effects of nintedanib (BIBF 1120) in primary human lung fibroblasts derived from patients with idiopathic pulmonary fibrosis and from non-fibrotic controls. Am. J. Respir. Crit. Care Med. 2013, 187, Abstract A3374.
8. Wollin, L.; Ostermann, A.; Wex, E.; Herrmann, F. E.; Doods, H. Nintedanib attenuates motility of lung fibroblasts from patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2014, 189, Abstract A2008.
9. Sandler, A.; Gray, R.; Perry, M. C.; Brahmer, J.; Schiller, J. H.; Dowlati, A.; Lilenbaum, R.; Johnson, D. H. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N. Engl. J. Med. 2006, 355, 2542-2550
10. Hurwitz, H.; Fehrenbacher, L.; Novotny, W.; Cartwright, T.; Hainsworth, J.; Heim, W.; Berlin, J.; Baron, A.; Griffing, S.; Holmgren, E.; Ferrara, N.; Fyfe, G.; Rogers, B.; Ross, R.; Kabbinavar, F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N. Engl. J. Med. 2004, 350, 2335-2342
11. Ferrara, N. Pathways mediating VEGF-independent tumor angiogenesis Cytokine Growth Factor Rev. 2010, 21, 21-26
12. Soria, J. C.; Mauguen, A.; Reck, M.; Sandler, A. B.; Saijo, N.; Johnson, D. H.; Burcoveanu, D.; Fukuoka, M.; Besse, B.; Pignon, J. P. meta-analysis of bevacizumab in advanced NSCLC collaborative group. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer Ann. Oncol. 2013, 24, 20-30
13. Korc, M.; Friesel, R. E. The role of fibroblast growth factors in tumor growth Curr. Cancer Drug Targets 2009, 9, 639-651
14. Lindner, V.; Majack, R. A.; Reidy, M. A. Basic fibroblast growth factor stimulates endothelial regrowth and proliferation in denuded arteries J. Clin. Invest. 1990, 85, 2004-2008
15. Berger, W.; Setinek, U.; Mohr, T.; Kindas-Mugge, I.; Vetterlein, M.; Dekan, G.; Eckersberger, F.; Caldas, C.; Micksche, M. Evidence for a role of FGF-2 and FGF receptors in the proliferation of non-small cell lung cancer cells Int. J. Cancer 1999, 83, 415-423
16. Ho, H. K.; Yeo, A. H.; Kang, T. S.; Chua, B. T. Current strategies for inhibiting FGFR activities in clinical applications: opportunities, challenges and toxicological considerations Drug Discovery Today 2014, 19, 51-62
17. Heldin, C. H. Targeting the PDGF signaling pathway in tumor treatment Cell Commun. Signal 2013, 11, 97
18. Raghu, G.; Collard, H. R.; Egan, J. J.; Martinez, F. J.; Behr, J.; Brown, K. K.; Colby, T. V.; Cordier, J. F.; Flaherty, K. R.; Lasky, J. A.; Lynch, D. A.; Ryu, J. H.; Swigris, J. J.; Wells, A. U.; Ancochea, J.; Bouros, D.; Carvalho, C.; Costabel, U.; Ebina, M.; Hansell, D. M.; Johkoh, T.; Kim, D. S.; King, T. E., Jr.; Kondoh, Y.; Myers, J.; Muller, N. L.; Nicholson, A. G.; Richeldi, L.; Selman, M.; Dudden, R. F.; Griss, B. S.; Protzko, S. L.; Schunemann, H. J. ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management Am. J. Respir. Crit. Care Med. 2011, 183, 788-824
19. Fernandez, I. E.; Eickelberg, O. The impact of TGF-beta on lung fibrosis: from targeting to biomarkers Proc. Am. Thorac. Soc. 2012, 9, 111-1116
20. Inoue, Y.; King, T. E., Jr.; Barker, E.; Daniloff, E.; Newman, L. S. Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis Am. J. Respir. Crit. Care Med. 2002, 166, 765-773
21. Hetzel, M.; Bachem, M.; Anders, D.; Trischler, G.; Faehling, M. Different effects of growth factors on proliferation and matrix production of normal and fibrotic human lung fibroblasts Lung 2005, 183, 225-237
22. Yu, Z. H.; Wang, D. D.; Zhou, Z. Y.; He, S. L.; Chen, A. A.; Wang, J. Mutant soluble ectodomain of fibroblast growth factor receptor-2 IIIc attenuates bleomycin-induced pulmonary fibrosis in mice Biol. Pharm. Bull. 2012, 35, 731-736
23. Chetta, A.; Zanini, A.; Foresi, A.; D'Ippolito, R.; Tipa, A.; Castagnaro, A.; Baraldo, S.; Neri, M.; Saetta, M.; Olivieri, D. Vascular endothelial growth factor up-regulation and bronchial wall remodelling in asthma Clin. Exp. Allergy 2005, 35, 1437-1442
24. Hamada, N.; Kuwano, K.; Yamada, M.; Hagimoto, N.; Hiasa, K.; Egashira, K.; Nakashima, N.; Maeyama, T.; Yoshimi, M.; Nakanishi, Y. Anti-vascular endothelial growth factor gene therapy attenuates lung injury and fibrosis in mice J. Immunol. 2005, 175, 1224-1231
25. Stopfer, P.; Rathgen, K.; Bischoff, D.; Lüdtke, S.; Marzin, K.; Kaiser, R.; Wagner, K.; Ebner, T. Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers Xenobiotica 2011, 41, 297-311
26. Stopfer, P.; Roth, W.; Mross, K.; Judson, I. R.; Kienast, J.; Kaiser, R.; Stefanic, M. Pharmacokinetic characterization of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) in advanced cancer patients Eur. J. Cancer Suppl. 2006, 4, 26 (Abstract 73)
27. Mross, K.; Stefanic, M.; Gmehling, D.; Frost, A.; Baas, F.; Unger, C.; Strecker, R.; Henning, J.; Gaschler-Markefski, B.; Stopfer, P.; de Rossi, L.; Kaiser, R. Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors Clin. Cancer Res. 2010, 16, 311-319
28. Okamoto, I.; Kaneda, H.; Satoh, T.; Okamoto, W.; Miyazaki, M.; Morinaga, R.; Ueda, S.; Terashima, M.; Tsuya, A.; Sarashina, A.; Konishi, K.; Arao, T.; Nishio, K.; Kaiser, R.; Nakagawa, K. Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors Mol. Cancer Ther. 2010, 9, 2825-2833
29. Kropff, M.; Kienast, J.; Bisping, G.; Berdel, W. E.; Gaschler-Markefski, B.; Stopfer, P.; Stefanic, M.; Munzert, G. An open-label dose-escalation study of BIBF 1120 in patients with relapsed or refractory multiple myeloma Anticancer Res. 2009, 29, 4233-4238
30. Doebele, R. C.; Conkling, P.; Traynor, A. M.; Otterson, G. A.; Zhao, Y.; Wind, S.; Stopfer, P.; Kaiser, R.; Camidge, D. R. A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer Ann. Oncol. 2012, 23, 2094-2102
31. Ellis, P. M.; Kaiser, R.; Zhao, Y.; Stopfer, P.; Gyorffy, S.; Hanna, N. Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients Clin. Cancer Res. 2010, 16, 2881-2889
32. Bousquet, G.; Alexandre, J.; Le Tourneau, C.; Goldwasser, F.; Faivre, S.; de Mont-Serrat, H.; Kaiser, R.; Misset, J. L.; Raymond, E. Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients Br. J. Cancer 2011, 105, 1640-1645
33. du Bois, A.; Huober, J.; Stopfer, P.; Pfisterer, J.; Wimberger, P.; Loibl, S.; Reichardt, V. L.; Harter, P. A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies Ann. Oncol. 2010, 21, 370-375
34. Reck, M.; Kaiser, R.; Eschbach, C.; Stefanic, M.; Love, J.; Gatzemeier, U.; Stopfer, P.; von Pawel, J. A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer Ann. Oncol. 2011, 22, 1374-1381
35. Van Cutsem, E.; Prenen, H.; Guillen-Ponce, C. A phase I/II, open-label, randomised study of BIBF 1120 plus mFOLFOX6 compared to bevacizumab plus FOLFOX6 in patients with metastatic colorectal cancer. Eur. J. Cancer 2011, 47, Abstract 14LBA.
36. Eisen, T.; Shparyk, Y.; Macleod, N.; Jones, R.; Wallenstein, G.; Temple, G.; Khder, Y.; Dallinger, C.; Studeny, M.; Loembe, A. B.; Bondarenko, I. Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study Invest. New Drugs 2013, 31, 1283-1293
37. Prenen, H.; D'Haens, G.; Capdevila, J.; Carrato, A.; Sobrero, A.; Ducreux, M.; François, E.; Staines, H.; Amellal, N.; Van Cutsem, E. A phase I dose escalation study of BIBF 1120 combined with FOLFOX in metastatic colorectal cancer (mCRC) patients. J. Clin. Oncol. 2010, 28, Abstract e14054.
38. Reck, M.; Kaiser, R.; Mellemgaard, A.; Douillard, J. Y.; Orlov, S.; Krzakowski, M.; von Pawel, J.; Gottfried, M.; Bondarenko, I.; Liao, M.; Gann, C. N.; Barrueco, J.; Gaschler-Markefski, B.; Novello, S.; LUME-Lung 1 Study Group Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial Lancet Oncol. 2014, 15, 143-155
39. Hanna, N.; Kaiser, R.; Kim, J. H.; Sullivan, R.; Aren, O.; Ahn, M. J.; Tiangco, B. J.; Voccia, I.; Barrueco, J.; Glomb, P. Retrospective evaluation of the futility analysis in LUME Lung 2, a randomized, double-blind, placebo-controlled phase 3 trial of nintedanib (BIBF 1120) in combination with pemetrexed in NSCLC patients progressing after one prior first line chemotherapy Ann. Oncol. 2013, 49, S802
40. Hanna, N. H.; Kaiser, R.; Sullivan, R. N.; Aren, O. R.; Ahn, M. J.; Tiangco, B. J.; Zvirbule, Z.; Barrios, C. H.; Demirkazik, A.; Gaschler-Markefski, B.; Voccia, I.; Barrueco, J.; Kim, J. H. Lume-lung 2: A multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy J. Clin. Oncol. 2013, 31, 8034
41. du Bois, A.; Kristensen, G.; Ray-Coquard, I.; Reuß, A.; Pignata, S.; Colombo, N.; Denison, U.; Vergote, I.; del Campo, J. M.; Ottevanger, P.; Merger, M.; Harter, P. AGO-Ovar 12: A randomized placebo-controlled GCIG/ENGOT-intergroup phase III trial of standard frontline chemotherapy ± nintedanib for advanced ovarian cancer. Int. J. Gynecol. Cancer 2013, 23, Abstract.
42. Ledermann, J. A.; Hackshaw, A.; Kaye, S.; Jayson, G.; Gabra, H.; McNeish, I.; Earl, H.; Perren, T.; Gore, M.; Persic, M.; Adams, M.; James, L.; Temple, G.; Merger, M.; Rustin, G. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer J. Clin. Oncol. 2011, 29, 3798-3804
43. Van Cutsem, E.; Prenen, H.; Guillen-Ponce, C.; Bennouna, J.; Di Benedetto, M.; Bouche, O.; Staines, H.; Oum'Hamed, Z.; Studeny, M.; Capdevila, J. A phase I/II, open-label, randomised study of BIBF 1120 plus mFOLFOX6 compared to bevacizumab plus mFOLFOX6 in patients with metastatic colorectal cancer Eur. J. Cancer 2011, 47, 8-9
44. Eisen, T.; Shparyk, Y.; Jones, R.; Macleod, N. J.; Temple, G.; Finnigan, H.; Kaiser, R.; Studeny, M.; Loembe, A. B.; Bondarenko, I. Phase II efficacy and safety study of nintedanib versus sunitinib in previously untreated renal cell carcinoma (RCC) patients. J. Clin. Oncol. 2013, 31, Abstract 4506.
45. Yen, C.; Kim, T. Y.; Feng, Y. H.; Chao, Y.; Lin, D. Y.; Studeny, M.; Hocke, J.; Huang, D. C. L.; Ryoo, B. Y.; Cheng, A. L. Efficacy and safety of nintedanib vs sorafenib in Asian patients with advanced hepatocellular carcinoma (HCC): a randomised Phase II trial Eur. J. Cancer 2013, 49, S612 (Abstract 2580)
46. Richeldi, L.; Costabel, U.; Selman, M.; Kim, D. S.; Hansell, D. M.; Nicholson, A. G.; Brown, K. K.; Flaherty, K. R.; Noble, P. W.; Raghu, G.; Brun, M.; Gupta, A.; Juhel, N.; Kluglich, M.; du Bois, R. M. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis N. Engl. J. Med. 2011, 365, 1079-1087
47. Richeldi, L.; du Bois, R. M.; Raghu, G.; Azuma, A.; Brown, K. K.; Costabel, U.; Cottin, V.; Flaherty, K. R.; Hansell, D. M.; Inoue, Y.; Kim, D. S.; Kolb, M.; Nicholson, A. G.; Noble, P. W.; Selman, M.; Taniguchi, H.; Brun, M.; Le Maulf, F.; Girard, M.; Stowasser, S.; Schlenker-Herceg, R.; Disse, B.; Collard, H. R. INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis N. Engl. J. Med. 2014, 370, 2071-2082
48. Jubb, A. M.; Harris, A. L. Biomarkers to predict the clinical efficacy of bevacizumab in cancer Lancet Oncol. 2010, 11, 1172-1183
49. Kaiser, R.; Barrueco, J. R.; Reck, M.; Hanna, N.; Gann, C.; Glomb, P.; Gaschler-Markefski, B. Identification of a clinical biomarker for 2nd line combination with nintedanib in adenocarcinoma non-small cell lung cancer (NSCLC) patients in two phase III trials Eur. J. Cancer 2013, 49, S822
50. Reck, M.; Novello, S.; Mellemgaard, A.; Orlov, S.; Kaiser, R.; Barrueco, J.; Gaschler-Markefski, B.; Douillard, J. Y. Impact of tumor burden on the overall survival analysis of the LUME-Lung 1 study: A randomized, double-blind phase 3 trial of nintedanib (BIBF 1120) + docetaxel in NSCLC patients progressing after first-line chemotherapy. J. Thorac. Oncol. 2013, 8, Presented at WCLC 2013, Abstract O16.01.
51. Hilberg, F.; Haslinger, C.; Garin-Chesa, P.; Adolf, G. R. Molecular correlates of clinical benefit from anti-angiogenic therapy of lung adenocarcinoma: a hypothesis. J. Clin. Oncol. 2014, Presented at ASCO 2014, Abstract e22080.
52. Demedts, M.; Costabel, U. ATS/ERS international multidisciplinary consensus classification of the idiopathic interstitial pneumonias Eur. Respir. J. 2002, 19, 794-796
53. Zhang, Y.; Kaminski, N. Biomarkers in idiopathic pulmonary fibrosis Curr. Opin. Pulm. Med. 2012, 18, 441-446
54. CHMP summary of positive opinion for Vargatef. September 25, 2014. http://www.ema.europa.eu/docs/en-GB/document-library/Summary-of-opinion-Initial-authorisation/human/002569/WC500173607.pdf (accessed November 2014).
55. FDA approves Ofev to treat idiopathic pulmonary fibrosis. October 15, 2014. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm418994.htm (accessed November 2014).